| abstract |
A combination treatment of an immunosuppressive adjuvant and a disease-specific antigen provides short and long term benefits for diseases associated with hyperactive immune responses. Such diseases include autoimmune diseases, transplantation rejection, and allergic diseases. The treatment can employ protein or nucleic acid delivery agents for antigen specific immunization. The immunosuppressive adjuvant inhibits the differentiation of dendritic cells and stimulates the expansion of Treg cells, in particular antigen-specific Treg cells. |